In the US and Europe, saxagliptin has been approved for use in patients with type 2 diabetes, both as monotherapy and in combination with metformin, a sulfonylurea, thiazolidinedione, or insulin, and also in combination with metformin plus insulin. Here, INS is linked to type 2 diabetes mellitus.